Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04896112
Recruitment Status : Recruiting
First Posted : May 21, 2021
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
Lynk Pharmaceuticals Co., Ltd

Brief Summary:
This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid leukemia (AML).

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Drug: LNK01002 Phase 1

Detailed Description:

This is a Phase I, open-label, dose-finding study of the triple kinase inhibitor LNK01002 in patients with myelofibrosis (MF). The study consists of two periods: the dose escalation, main period and a dose expansion period. In the dose escalation period, successive cohorts of patients with MF will be enrolled to establish the maximum tolerated dose. In the dose expansion period (dose-confirmation phase), three cohorts of patients will be enrolled: AML patients with confirmed FLT3-ITD mutations, AML patients without FLT3-ITD mutations, and patients with primary MF or PV/ET-MF.

The safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of LNK01002 in patients with myelofibrosis/AML will be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 93 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
Actual Study Start Date : April 8, 2021
Estimated Primary Completion Date : October 23, 2023
Estimated Study Completion Date : December 23, 2023


Arm Intervention/treatment
Experimental: Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg
Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg
LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 45 mg
LNK01002 45 mg BID, followed by a 3-day observation period then 45 mg BID in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg
LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 80 mg
LNK01002 80 mg BID, followed by a 3-day observation period then 80 mg BID in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg
LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Acute Myeloid Leukemia With Mutant FLT3
LNK01002 at the RP2D dose in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3
LNK01002 at the RP2D dose in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318

Experimental: Patients with Primary or Secondary Myelofibrosis
LNK01002 at the RP2D dose in 28-day treatment cycles
Drug: LNK01002
LNK01002 will be administrated orally.
Other Name: LNK-1000318




Primary Outcome Measures :
  1. Assessing the safety and tolerability of LNK01002 in patients with myelofibrosis [ Time Frame: 31 days ]
    Assessed by monitoring the frequency, duration and severity of adverse events and serious adverse events.

  2. Assessing maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of LNK01002 in patients with myelofibrosis [ Time Frame: 31 days ]
    Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) will be assessed based on the safety profile by the SRC

  3. Assessing the preliminary antitumor activity of LNK01002 [ Time Frame: 24 Weeks ]
    The preliminary antitumor activity will be analyzed in patients with different types of malignant myeloid hematologic neoplasms by response rate using bone marrow and hematologic analyses (MF/AML) or by the MF Symptom Assessment Scale and spleen volume by MRI (MF).


Secondary Outcome Measures :
  1. Measurement of pharmacokinetic (PK) parameter, AUC, in MF, PV-MF or ET-MF patients [ Time Frame: Day 1, Day 2, and Day 15 ]
    Measurement will be using extensive PK sampling

  2. Measurement of pharmacokinetic (PK) parameter, Cmax, in MF, PV-MF or ET-MF patients [ Time Frame: Day 1, Day 2, and Day 15 ]
    Measurement will be using extensive PK sampling

  3. Measurement of pharmacokinetic (PK) parameter, Tmax, in MF, PV-MF or ET-MF patients [ Time Frame: Day 1, Day 2, and Day 15 ]
    Measurement will be using extensive PK sampling

  4. Measurement of pharmacokinetic (PK) parameter, CL/F, in MF, PV-MF or ET-MF patients [ Time Frame: Day 1, Day 2, and Day 15 ]
    Measurement will be using extensive PK sampling

  5. Measurement of pharmacokinetic (PK) parameter, T1/2, in MF, PV-MF or ET-MF patients [ Time Frame: Day 1, Day 2, and Day 15 ]
    Measurement will be using extensive PK sampling

  6. Measurement of pharmacokinetic (PK) parameter, Vz/F, in MF, PV-MF or ET-MF patients [ Time Frame: Day 1, Day 2, and Day 15 ]
    Measurement will be using extensive PK sampling

  7. Measurement of pharmacokinetic (PK) parameter, MRT, in MF, PV-MF or ET-MF patients [ Time Frame: Day 1, Day 2, and Day 15 ]
    Measurement will be using extensive PK sampling



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 18 years old or older, male or female.
  2. Patients must have histologically or cytologically confirmed tumors of the following types.
  3. Dose Escalation Phase: Patients with PMF, PV/ET-MF

    1. Intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis which failed standard treatment.
    2. Symptomatic splenomegaly
    3. Not undergone splenectomy or splenic radiation therapy within 6 months prior to screening.
  4. Dose expansion phase: Patients with PMF, PV/ET-MF who relapsed or are intolerant to standard treatment, and relapsed/refractory AML
  5. Platelet count ≥ 100 × 10e9/L within 14 days before study drug administration
  6. Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L within 14 days before study drug administration
  7. Women of childbearing potential negative pregnancy test at screening. Female patients of childbearing potential, or male patients and their partners should agree to effective contraception from signing ICF until 6 months after the last dose of study drug.

Exclusion Criteria:

Patients who meet any of the following exclusion criteria will be excluded from the clinical study:

  1. Allergic to any component of LNK01002.
  2. Serum total bilirubin greater than 1.5 times the upper limit of the normal (ULN) reference range, except patients diagnosed as Gilbert's disease
  3. ALT or AST higher than 3 times the ULN reference range without hepatic involvement by leukemia, which are excluded if higher than 5 times the ULN
  4. Glomerular filtration rate or estimated creatinine clearance < 50 mL/min according to the Cockcroft-Gault formula;
  5. Serum amylase or lipase levels higher than the ULN and considered clinically significant
  6. International normalized ratio (INR) or partial activated prothrombin time (aPTT) above 1.5 times the ULN reference range
  7. Known history of clinically significant liver disease, including viral or other hepatitis:

    a) Patients with hepatitis B or hepatitis C may be enrolled if they have a negative polymerase chain reaction (PCR)

  8. Known human immunodeficiency virus (HIV) infection;
  9. Clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass surgery within 6 months before enrollment, congestive heart failure with New York Heart Association (NYHA) classification of III or above, left ventricular ejection fraction (LVEF) < 50%, or uncontrolled hypertension, cardiac arrhythmia;
  10. Patients with history or presence of clinically relevant non-malignant CNS disease requiring treatment
  11. Patients who have received systemic antineoplastic therapy or radiotherapy within 2 weeks prior to start of study treatment:
  12. Patients who have received hematopoietic stem cell transplantation (HSCT) within 60 days prior to the start of study treatment, or are receiving immunosuppressive therapy after HSCT at screening, or have graft-versus-host disease (GVHD) requiring drug control:
  13. Received anti-tumor Chinese herbal medicine treatment within 1 week before the start of study treatment;
  14. Received CYP3A substrates, CYP2B6 substrates, CYP2C substrates, OATP1B3 substrates, UGT1A1 inhibitors, or UGT1A3 inhibitors less than one week or 5 half-lives (whichever is longer) prior to the start of study treatment;
  15. Uncontrolled, active infections requiring intravenous antibiotic treatment;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04896112


Contacts
Layout table for location contacts
Contact: Peter Langecker, M.D. 408-656-9855 plangecker@clinipace.com
Contact: Sherry Weigand, M.D., Ph.D. 617-678-5412 sweigand1@lynkpharma.com

Locations
Layout table for location information
United States, Michigan
Revive Research Institute Recruiting
Farmington Hills, Michigan, United States, 48334
Contact: Samuel Ceckowski    248-721-9539    sceckowski@rev-research.com   
Contact: Balaraman         
Principal Investigator: Savitha Balaraman, M.D.         
Revive Research Institute Recruiting
Sterling Heights, Michigan, United States, 48314
Contact: Mohammed Ali    248-238-6010    mali@rev-research.com   
Principal Investigator: Adil Akhtar, M.D.         
Sponsors and Collaborators
Lynk Pharmaceuticals Co., Ltd
Investigators
Layout table for investigator information
Study Director: Sherry Weigand, M.D., Ph.D. Lynk Pharmaceuticals Co., Ltd
Layout table for additonal information
Responsible Party: Lynk Pharmaceuticals Co., Ltd
ClinicalTrials.gov Identifier: NCT04896112    
Other Study ID Numbers: LNK-1002-01
IND 153144 ( Registry Identifier: FDA )
First Posted: May 21, 2021    Key Record Dates
Last Update Posted: June 9, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lynk Pharmaceuticals Co., Ltd:
Acute Myeloid Leukemia
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Myeloid malignancies
Myelofibrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Polycythemia Vera
Primary Myelofibrosis
Polycythemia
Thrombocytosis
Thrombocythemia, Essential
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Blood Platelet Disorders
Blood Coagulation Disorders
Hemorrhagic Disorders